Domperidone for milk supply: what the evidence actually shows

What's this video probably claiming?

Based on the hashtags, this creator is almost certainly sharing her personal experience using domperidone to boost milk supply, likely as a pumping mom dealing with low production, possibly complicated by PCOS. The PCOS tag is significant. Women with polycystic ovary syndrome have documented rates of low milk supply due to hormonal dysregulation, insulin resistance, and sometimes insufficient glandular tissue. The creator appears to be framing domperidone as a solution, probably describing a pumping output increase, a dosing routine she picked up somewhere, or a recommendation from a provider. Videos like this tend to follow a testimonial arc: struggling mom, discovers medication, sees results, shares with other pumping moms. The problem is that domperidone is not FDA-approved in the United States for any indication, including lactation support, and the gap between personal anecdote and clinical evidence matters enormously here.

What does the science actually show?

Domperidone is a dopamine antagonist that raises prolactin levels by blocking dopamine receptors in the pituitary. It does have real evidence behind it for lactation. A randomized controlled trial by da Silva et al. (2001, BJOG) found that mothers of preterm infants taking 10mg three times daily produced significantly more milk than placebo groups after two weeks. Wan et al. (2008, Breastfeeding Medicine) found similar results in mothers of NICU infants. The effect size is real but modest, typically 40 to 90 percent increases in output in the most responsive populations, and that population tends to be mothers with established but insufficient supply, not those with primary lactation failure. Critically, domperidone's cardiac risk profile, specifically QT interval prolongation, led Health Canada to issue a warning and the FDA to ban its importation. That risk context rarely makes it into TikTok testimonials.

Where does the social media noise diverge from clinical reality?

The gap between how domperidone gets discussed online versus how clinicians think about it is substantial. Social media treatments of this drug tend to skip three things entirely. First, the cardiac risk. Health Canada's 2015 advisory specifically flagged doses above 30mg per day and use in people with underlying cardiac conditions as carrying meaningful QT prolongation risk, a potentially fatal arrhythmia. Second, the fact that without adequate breast stimulation, domperidone does very little. Prolactin alone does not produce milk if demand is not present. Third, PCOS-specific lactation challenges may not respond to prolactin elevation at all if the underlying issue is glandular insufficiency rather than suppressed prolactin.Emaral et al. (2019, Journal of Human Lactation) noted that PCOS-related low supply is multifactorial and often incompletely addressed by galactagogues alone. A TikTok success story is not a clinical trial.

What should you actually know?

If you are a pumping mom in the US researching domperidone, here is what the evidence actually supports. Domperidone has legitimate, peer-reviewed evidence for increasing milk output in certain populations, particularly mothers of preterm infants. It is not a guaranteed fix, it is not FDA-approved, and obtaining it in the US without a compounding pharmacy or importation creates real regulatory and safety concerns. If you have PCOS, talk with a provider about whether your low supply is hormonal, structural, or both before reaching for any galactagogue. The International Breastfeeding Journal and Academy of Breastfeeding Medicine's 2018 clinical protocol on galactagogues both recommend that domperidone be used only when non-pharmacological measures have been tried first, at the lowest effective dose, with cardiac screening where appropriate. A TikTok caption with a domperidone hashtag should not be your protocol.